產(chǎn)品[
HB-82 BB7.2小鼠 雜交瘤 B**細(xì)胞
]資料
如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
HB-82 BB7.2小鼠 雜交瘤 B**細(xì)胞
產(chǎn)品型號:
BB7.2
產(chǎn)品廠商:
美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡單介紹
HB-82 BB7.2小鼠 雜交瘤 B**細(xì)胞，ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞株|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和Z優(yōu)培養(yǎng)條件
HB-82 BB7.2小鼠 雜交瘤 B**細(xì)胞
的詳細(xì)介紹
HB-82 BB7.2小鼠 雜交瘤 B**細(xì)胞
|
|
HB-82?
|
|
$399.00
|
|
|
BB7.2
|
|
|
P Parham
|
|
|
IgG2b
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension
|
|
|
Mus musculus (B cell); Mus musculus (myeloma) (mouse (B cell); mouse (myeloma))
|
|
|
lymphoblast
|
|
|
Cell Type: hybridoma: B lymphocyte;
|
|
|
immunoglobulin; monoclonal antibody; against HLA A2, Aw69; cytotoxic
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
|
|
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
|
|
|
950: Parham P, Brodsky FM. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3: 277-299, 1981. PubMed: 7035415
32263: Cole DJ, et al. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res. 57: 5320-5327, 1997. PubMed: 9393756
39935: Santos-Aguado J, et al. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J. Immunol. 141: 2811-2818, 1988. PubMed: 2459229
39936: Hogan KT, Brown SL. Localization and characterization of serologic epitopes on HLA-A2. Hum. Immunol. 33: 185-192, 1992. PubMed: 1377666
|
|
ATCC® Number: HB-82? Price: $399.00
Designations: BB7.2
Depositors: P Parham
Isotype: IgG2b
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) (mouse (B cell); mouse (myeloma))
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against HLA A2, Aw69; cytotoxic
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Animals were immunized with papain solubilized HLA A2 antigen.
Spleen cells were fused with NS-1 myeloma cells.
Mutation at position 107 of the alpha 2 domain of the HLA-A2 molecule results in partial loss of BB7.2 binding. [39935]
BB7.2 and PA2.1 (ATCC HB-117) recognize overlapping epitopes on the alpha 2 domain of HLA-A2. [39936]
The antibody cross-reacts with cells from various primate species.
Tested and found negative for ectromelia virus (mousepox).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
References: 950: Parham P, Brodsky FM. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3: 277-299, 1981. PubMed: 7035415
32263: Cole DJ, et al. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res. 57: 5320-5327, 1997. PubMed: 9393756
39935: Santos-Aguado J, et al. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J. Immunol. 141: 2811-2818, 1988. PubMed: 2459229
39936: Hogan KT, Brown SL. Localization and characterization of serologic epitopes on HLA-A2. Hum. Immunol. 33: 185-192, 1992. PubMed: 1377666
